Effective anti-tuberculosis therapy correlates with plasma small RNA.
Centre for Clinical Microbiology, Dept of Infection, University College London, London, UK i.honeyborne@ucl.ac.uk.
Isobella
I
Honeyborne
Centre for Respiratory Medicine, University College London, London, UK.
Marc C
MC
Lipman
Centre for Clinical Microbiology, Dept of Infection, University College London, London, UK.
Clare
C
Eckold
Centre for Clinical Microbiology, Dept of Infection, University College London, London, UK.
Dimitrios
D
Evangelopoulos
School of Medicine, Medical and Biological Sciences, University of St Andrews, St Andrews, UK.
Stephen H
SH
Gillespie
K-RITH (KwaZulu-Natal Research Institute for Tuberculosis and HIV), Nelson R. Mandela School of Medicine, University of KwaZulu-Natal, Durban, South Africa.
Alexander
A
Pym
Centre for Clinical Microbiology, Dept of Infection, University College London, London, UK.
Timothy D
TD
McHugh
D000328:Adult; D000995:Antitubercular Agents / Q000627:therapeutic use*; D015415:Biomarkers / Q000097:blood; D060085:Coinfection; D004977:Ethambutol / Q000627:therapeutic use; D005260:Female; D020869:Gene Expression Profiling; D015658:HIV Infections / Q000150:complications; D006801:Humans; D007538:Isoniazid / Q000627:therapeutic use; D008297:Male; D035683:MicroRNAs / Q000097:blood; D011446:Prospective Studies; D011718:Pyrazinamide / Q000627:therapeutic use; D012313:RNA / Q000097:blood*; D012293:Rifampin / Q000627:therapeutic use; D016896:Treatment Outcome; D014397:Tuberculosis, Pulmonary / Q000150:complications / Q000188:drug therapy* / Q000235:genetics
D000995:Antitubercular Agents; D015415:Biomarkers; D035683:MicroRNAs; D011718:Pyrazinamide; D012313:RNA; D004977:Ethambutol; D007538:Isoniazid; D012293:Rifampin